Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Management of patients with multidrug-resistant tuberculosis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lange, C, Aarnoutse, RE, Alffenaar, JWC, Bothamley, G, Brinkmann, F, Costa, J, Chesov, D, van Crevel, R, Dedicoat, M, Dominguez, J, Duarte, R, Grobbel, HP, Günther, G, Guglielmetti, L, Heyckendorf, J, Kay, AW, Kirakosyan, O, Kirk, O, Koczulla, RA, Kudriashov, GG, Kuksa, L, van Leth, F, Magis-Escurra, C, Mandalakas, AM, Molina-Moya, B, Peloquin, CA, Reimann, M, Rumetshofer, R, Schaaf, HS, Schön, T, Tiberi, S, Valda, J, Yablonskii, PK & Dheda, K 2019, 'Management of patients with multidrug-resistant tuberculosis' The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, vol. 23, no. 6, pp. 645-662. https://doi.org/10.5588/ijtld.18.0622

APA

CBE

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K. 2019. Management of patients with multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 23(6):645-662. https://doi.org/10.5588/ijtld.18.0622

MLA

Vancouver

Author

Lange, C ; Aarnoutse, R E ; Alffenaar, J W C ; Bothamley, G ; Brinkmann, F ; Costa, J ; Chesov, D ; van Crevel, R ; Dedicoat, M ; Dominguez, J ; Duarte, R ; Grobbel, H P ; Günther, G ; Guglielmetti, L ; Heyckendorf, J ; Kay, A W ; Kirakosyan, O ; Kirk, O ; Koczulla, R A ; Kudriashov, G G ; Kuksa, L ; van Leth, F ; Magis-Escurra, C ; Mandalakas, A M ; Molina-Moya, B ; Peloquin, C A ; Reimann, M ; Rumetshofer, R ; Schaaf, H S ; Schön, T ; Tiberi, S ; Valda, J ; Yablonskii, P K ; Dheda, K. / Management of patients with multidrug-resistant tuberculosis. In: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2019 ; Vol. 23, No. 6. pp. 645-662.

Bibtex

@article{bbad6e9ffbfc4b19bd891a8d30ca9cb3,
title = "Management of patients with multidrug-resistant tuberculosis",
abstract = "The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, treatment is prolonged, adverse events are common, and the majority of affected patients do not receive adequate treatment. As MDR-TB strains are often resistant to one or more second-line anti-TB drugs, in-depth genotypic and phenotypic drug susceptibility testing is needed to construct personalised treatment regimens to improve treatment outcomes. For the first time in decades, the availability of novel drugs such as bedaquiline allow us to design potent and well-tolerated personalised MDR-TB treatment regimens based solely on oral drugs. In this article, we present management guidance to optimise the diagnosis, algorithm-based treatment, drug dosing and therapeutic drug monitoring, and the management of adverse events and comorbidities, associated with MDR-TB. We also discuss the role of surgery, physiotherapy, rehabilitation, palliative care and smoking cessation in patients with MDR-TB. We hope that incorporating these recommendations into patient care will be helpful in optimising treatment outcomes, and lead to more MDR-TB patients achieving a relapse-free cure.",
author = "C Lange and Aarnoutse, {R E} and Alffenaar, {J W C} and G Bothamley and F Brinkmann and J Costa and D Chesov and {van Crevel}, R and M Dedicoat and J Dominguez and R Duarte and Grobbel, {H P} and G G{\"u}nther and L Guglielmetti and J Heyckendorf and Kay, {A W} and O Kirakosyan and O Kirk and Koczulla, {R A} and Kudriashov, {G G} and L Kuksa and {van Leth}, F and C Magis-Escurra and Mandalakas, {A M} and B Molina-Moya and Peloquin, {C A} and M Reimann and R Rumetshofer and Schaaf, {H S} and T Sch{\"o}n and S Tiberi and J Valda and Yablonskii, {P K} and K Dheda",
year = "2019",
month = "6",
day = "1",
doi = "10.5588/ijtld.18.0622",
language = "English",
volume = "23",
pages = "645--662",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tuberculosis and Lung Disease (I U A T L D)",
number = "6",

}

RIS

TY - JOUR

T1 - Management of patients with multidrug-resistant tuberculosis

AU - Lange, C

AU - Aarnoutse, R E

AU - Alffenaar, J W C

AU - Bothamley, G

AU - Brinkmann, F

AU - Costa, J

AU - Chesov, D

AU - van Crevel, R

AU - Dedicoat, M

AU - Dominguez, J

AU - Duarte, R

AU - Grobbel, H P

AU - Günther, G

AU - Guglielmetti, L

AU - Heyckendorf, J

AU - Kay, A W

AU - Kirakosyan, O

AU - Kirk, O

AU - Koczulla, R A

AU - Kudriashov, G G

AU - Kuksa, L

AU - van Leth, F

AU - Magis-Escurra, C

AU - Mandalakas, A M

AU - Molina-Moya, B

AU - Peloquin, C A

AU - Reimann, M

AU - Rumetshofer, R

AU - Schaaf, H S

AU - Schön, T

AU - Tiberi, S

AU - Valda, J

AU - Yablonskii, P K

AU - Dheda, K

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, treatment is prolonged, adverse events are common, and the majority of affected patients do not receive adequate treatment. As MDR-TB strains are often resistant to one or more second-line anti-TB drugs, in-depth genotypic and phenotypic drug susceptibility testing is needed to construct personalised treatment regimens to improve treatment outcomes. For the first time in decades, the availability of novel drugs such as bedaquiline allow us to design potent and well-tolerated personalised MDR-TB treatment regimens based solely on oral drugs. In this article, we present management guidance to optimise the diagnosis, algorithm-based treatment, drug dosing and therapeutic drug monitoring, and the management of adverse events and comorbidities, associated with MDR-TB. We also discuss the role of surgery, physiotherapy, rehabilitation, palliative care and smoking cessation in patients with MDR-TB. We hope that incorporating these recommendations into patient care will be helpful in optimising treatment outcomes, and lead to more MDR-TB patients achieving a relapse-free cure.

AB - The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, treatment is prolonged, adverse events are common, and the majority of affected patients do not receive adequate treatment. As MDR-TB strains are often resistant to one or more second-line anti-TB drugs, in-depth genotypic and phenotypic drug susceptibility testing is needed to construct personalised treatment regimens to improve treatment outcomes. For the first time in decades, the availability of novel drugs such as bedaquiline allow us to design potent and well-tolerated personalised MDR-TB treatment regimens based solely on oral drugs. In this article, we present management guidance to optimise the diagnosis, algorithm-based treatment, drug dosing and therapeutic drug monitoring, and the management of adverse events and comorbidities, associated with MDR-TB. We also discuss the role of surgery, physiotherapy, rehabilitation, palliative care and smoking cessation in patients with MDR-TB. We hope that incorporating these recommendations into patient care will be helpful in optimising treatment outcomes, and lead to more MDR-TB patients achieving a relapse-free cure.

U2 - 10.5588/ijtld.18.0622

DO - 10.5588/ijtld.18.0622

M3 - Journal article

VL - 23

SP - 645

EP - 662

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 6

ER -

ID: 59238545